IMMP - Immutep rises ~15% as eftilagimod combo shows promise in phase 1 lung cancer trial

2023-05-24 09:22:54 ET

Immutep ( NASDAQ: IMMP ) said its drug eftilagimod alpha plus standard-of-care anti-PD-1 therapy and doublet chemotherapy in first line non-small cell lung cancer (NSCLC) was well tolerated and showed promising initial signals of efficacy in a phase 1 trial.

The study called INSIGHT-003 — was conducted by the Frankfurt Institute of Clinical Cancer Research IKF — evaluated efti with standard-of-care anti-PD-1 therapy and doublet chemotherapy (carboplatin/pemetrexed).

The triple combination attained a 67% overall response rate (ORR) and 91% disease control rate (DCR) in patients with advanced or metastatic non-squamous 1st line NSCLC (N=21).

The company added that 81% (17/21) of patients had a PD-L1 Tumor Proportion Score (TPS) of <50%, who are less responsive to anti-PD-1 based therapy compared with PD-L1 high expressing patients.

Immutep noted that the 67% ORR regardless of PD-L1 expression and 65% response rate (RR) in patients with PD-L1 TPS <50% for the triple combo compare favorably to data from a registrational trial of anti-PD-1 and doublet chemotherapy in the same patient population which saw an ORR of 48% regardless of PD-L1 expression and a RR of 40.8% in patients with PD-L1 TPS <50%.

"We are uniquely positioned to address PD-L1 low (TPS 1-49%) and high (TPS >50%) expressing patients, representing roughly 65% of the non-small cell lung cancer patient population, with powerful chemo-free IO-IO approaches, and potentially the entire patient population when including the IO-IO-chemo combination being tested in INSIGHT-003," said Immutep's CSO Frédéric Triebel.

IMMP +15.65% to $2.66 premarket May 24

More on Immutep

Immutep's Efti And Keytruda Combo Breaks New Ground In Immunotherapy

For further details see: